The Uromigos

Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1) 31.05.2020 17:41 ↓

Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO. 

Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough? 30.05.2020 20:40 ↓

Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret. 

Episode 33: Adjuvant Atezolizumab in Urothelial Cancer 29.05.2020 19:59 ↓

Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field. 

Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020 29.05.2020 24:09 ↓

Thomas Hope is quizzed on the results of his study presented at ASCO20.

Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer 29.05.2020 25:18 ↓

Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease. 

Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426) 29.05.2020 20:03 ↓

Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds. 

Episode 29: PSMA PET at ASCO 2020 with Mike Morris 29.05.2020 23:47 ↓

Mike Morris presents the findings in his prospective study. 

Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer 29.05.2020 13:31 ↓

Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome. 

Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19) 29.05.2020 21:44 ↓

Jeremy Warner summarises the recent Lancet paper describing the outcome of cancer patients with COVID-19. 

Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020 19.05.2020 22:23 ↓

Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20. 

Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial 19.05.2020 14:47 ↓

Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial.

Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality 28.04.2020 19:51 ↓

Marina Garassino and Leora Horn discuss their AACR study of COVID-19 in lung cancer.

Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer 28.04.2020 22:35 ↓

Chris Sweeney explains why the trial was negative and answers some of the questions.

Episode 22: COVID-19 and Cardiovascular Disease 22.04.2020 18:28 ↓

Kaushik Amancherla and Javid Moslehi discuss the link of COVID-19 and cardiovascular disease. Professor Tom Powles and Dr. Brian Rini struggle to keep up.

Episode 21: Treating cancer patients over the next year in the era of COVID-19 15.04.2020 12:33 ↓

The Uromigos struggle to describe what cancer care looks like in three months’ time during the COVID-19 pandemic.

Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection 15.04.2020 13:07 ↓

The Uromigos can’t agree on how to approach COVID-infected GU cancer patients who need systematic treatment.

Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer 15.04.2020 18:17 ↓

Professor Monty Pal discusses non-clear cell renal cancer while Dr. Brian Rini gets irritated by background interruptions. 

Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns 06.04.2020 24:46 ↓

Dena Battle presents a 500-patient survey on issues around COVID-19. Professor Tom Powles and Dr. Brian Rini attempt to address the issues raised.

Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19 02.04.2020 21:33 ↓

Professor Tom Powles, Dr. Brian Rini and Dr. Toni Choueiri discuss the evolving landscape in Boston, and meetings such as ASCO and ESMO in 2020.

Episode 16: Treatments and Trials for COVID-19 31.03.2020 25:31 ↓

Professor Nick Mark discusses the latest data on drug treatments and trials for COVID-19.

Episode 15: COVID-19 and Bladder Cancer Surgery 28.03.2020 14:52 ↓

The Uromigos discuss the practicalities in surgery for bladder cancer in the era of COVID-19 with Betsy Plimack (Fox Chase Cancer Center, Philadelphia)

Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle 24.03.2020 15:04 ↓

Dr. Brian Rini and Professor Tom Powles discuss the data and ongoing studies with the IL-6 antibody tocilizumab.

Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials 23.03.2020 18:44 ↓

Dr. David Boulware discusses existing data and ongoing prophylaxis studies.

Episode 12: COVID-19 in Cancer Patients - The Seattle Experience 20.03.2020 26:19 ↓

A discussion with doctors from the Fred Hutchinson Cancer Center in Seattle about COVID-19.

Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer 16.03.2020 17:43 ↓

Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic.